Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53

28 Jun 2011

Abstract excerpt

BACKGROUND: The aim of this study is to determine whether immunohistochemical (IHC) assessment of Ki67 and p53 improves prognostication of oestrogen receptor-positive (ER+) breast cancer after breast-conserving therapy (BCT). In all, 498 patients with invasive breast cancer from a randomised trial of BCT with or without tumour bed radiation boost were assessed using IHC. METHODS: The ER+ tumours were classified...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Breast Cancer Treatment Studies
Share to Medical Imaging Techniques and Applications

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21712826
DOI: 10.1038/bjc.2011.228

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 14 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53PMID 21712826Read ↗

Multimodal histopathologic models stratify hormone receptor-positive early breast cancerSemantic proximity Read ↗

Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancerSemantic proximity Read ↗

Comparing Molecular Biomarker Testing With Immunohistochemical Staining In Predicting Response To Neoadjuvant Therapy In Breast CancerSemantic proximity Read ↗

Molecular Classification of Estrogen Receptor-positive/Luminal Breast CancersSemantic proximity Read ↗

Type 1 Receptor Tyrosine Kinase Profiles Identify Patients With Enhanced Benefit From Anthracyclines in the BR9601 Adjuvant Breast Cancer Chemotherapy TrialSemantic proximity Read ↗

Radiation therapy following surgery for localized breast cancer: outcome prediction by classical prognostic factors and approximated genetic subtypes.Semantic proximity Read ↗

Evaluation and comparison of different breast cancer prognosis scores based on gene expression dataSemantic proximity Read ↗

Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype.Semantic proximity Read ↗

Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer CohortsSemantic proximity Read ↗

Looking for more reliable biomarkers in breast cancer: Comparison between routine methods and RT-qPCRSemantic proximity Read ↗

Clinicopathological characteristics of oestrogen receptor negative, progesterone receptor positive breast cancers: re-evaluating subsets within this group.Semantic proximity Read ↗

Associations Between the 21-Gene Oncotype DX Recurrence Score, Ki67, and Race in Early Breast Cancer: An Analysis of the National Cancer DatabaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.